Form 8-K - Current report:
SEC Accession No. 0001140361-26-021496
Filing Date
2026-05-15
Accepted
2026-05-15 07:50:30
Documents
13
Period of Report
2026-05-15
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K ef20073003_8k.htm   iXBRL 8-K 31160
2 EXHIBIT 99.1 ef20073003_ex99-1.htm EX-99.1 84132
6 image0.jpg GRAPHIC 426608
  Complete submission text file 0001140361-26-021496.txt   843307

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA galt-20260515.xsd EX-101.SCH 3901
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE galt-20260515_lab.xml EX-101.LAB 21966
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE galt-20260515_pre.xml EX-101.PRE 16068
16 EXTRACTED XBRL INSTANCE DOCUMENT ef20073003_8k_htm.xml XML 4244
Mailing Address 4960 PEACHTREE INDUSTRIAL BOULEVARD SUITE 240 NORCROSS GA 30071
Business Address 4960 PEACHTREE INDUSTRIAL BOULEVARD SUITE 240 NORCROSS GA 30071 678-620-3186
GALECTIN THERAPEUTICS INC (Filer) CIK: 0001133416 (see all company filings)

EIN.: 043562325 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-31791 | Film No.: 26982328
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)